BioWorld

Oct. 30, 2009

Another 'BiTE' as Micromet Inks Potential €320M Sanofi Alliance

With buzz growing about Micromet Inc.'s BiTE antibody blinatumomab (MT103) ahead of the upcoming American Society of Hematology meeting, the Bethesda, Md.-based firm scored an early stage deal with Sanofi-Aventis SA to develop another BiTE compound. (BioWorld Today) Read More

Transcept Plunges as FDA Cites Concerns About Insomnia Drug

Gene Fusions Are Not Random Events, but Aided by Hormones

Adjust-as-You-Go Trial Approach: Key to Pleasing FDA, Partners?

Aldagen Eyes Public Markets to Fund Two Phase III Efforts

Genta Crushed as Genasense Fails Another Phase III Study

Virdante Series A Brings in $47M to Boost New Antibody Program

Other News To Note

Clinic Roundup

Earnings Roundup

Today's news in brief

BioWorld

BioWorld briefs for July 30, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for July 28, 2026

Illustration of dopamine signaling in the brain

New schizophrenia targets challenge trial design

BioWorld

The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...

AIDS 2026: New targets for metabolic dysfunction despite ART

BioWorld

Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...

Regulatory actions for July 27, 2026

BioWorld

Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Alfasigma,...